SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and Schrodinger (NASDAQ:SDGR – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Valuation & Earnings
This table compares SOPHiA GENETICS and Schrodinger”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SOPHiA GENETICS | $77.27 million | 6.76 | -$79.00 million | ($1.09) | -5.72 |
| Schrodinger | $255.87 million | 6.72 | -$103.26 million | ($0.79) | -29.00 |
SOPHiA GENETICS has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 79.0% of Schrodinger shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent ratings and target prices for SOPHiA GENETICS and Schrodinger, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SOPHiA GENETICS | 1 | 1 | 3 | 0 | 2.40 |
| Schrodinger | 1 | 3 | 4 | 0 | 2.38 |
SOPHiA GENETICS presently has a consensus price target of $10.00, indicating a potential upside of 60.51%. Schrodinger has a consensus price target of $26.67, indicating a potential upside of 16.39%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, equities analysts plainly believe SOPHiA GENETICS is more favorable than Schrodinger.
Profitability
This table compares SOPHiA GENETICS and Schrodinger’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SOPHiA GENETICS | -89.18% | -128.69% | -44.73% |
| Schrodinger | -22.02% | -18.12% | -9.07% |
Risk and Volatility
SOPHiA GENETICS has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.
Summary
Schrodinger beats SOPHiA GENETICS on 9 of the 14 factors compared between the two stocks.
About SOPHiA GENETICS
SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.
About Schrodinger
Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
